Asialoglycoproteine des Hepatitis C-Virus
The following are claimed: (A) an isolated hepatitis C virus (HCV) a sialoglycoprotein (AG) selected from E1 and E2; (B) a method for purifying HCV AGs, which comprises (a) contacting a compsn. contg. HCV AGs with a mannose-binding protein, e.g. concanavalin A (ConA) or Galanthus nivalus agglutinin...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Format: | Patent |
| Sprache: | ger |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | GERVASE, BARBARA A THUDIUM, KENT B RALSTON, ROBERT O HALL, JOHN A MARCUS, FRANK |
| description | The following are claimed: (A) an isolated hepatitis C virus (HCV) a sialoglycoprotein (AG) selected from E1 and E2; (B) a method for purifying HCV AGs, which comprises (a) contacting a compsn. contg. HCV AGs with a mannose-binding protein, e.g. concanavalin A (ConA) or Galanthus nivalus agglutinin (GNA) and (b) isolating the portion of the compsn. which binds to the mannose-binding protein, e.g. by elution with mannose; (c) an assay kit for detecting the presence of HCV AGs, comprising (a) a solid support, (b) a mannose-binding protein, and (c) an antibody specific for the HCV AG, where one of the antibody and the mannose-binding protein is bound to the solid support; (D) a method for determining exposure to or infection by HCV, in which any HCV in a sample of body fluid is concd. by contact with a mannose-binding protein prior to assay; (E) a cell transformed with a vector for recombinant expression of a HCV AG, where the vector comprises a structural gene encoding a glycosoylation signal, a HCV AG, a regulatory sequence operable in the host cell and capable of regulating expressio fo the HCV AG, and a selectable marker, where the cell does not sialylate glycoproteins; and (F) a method for reducing or eliminatng the presence of HCV in plasma, serum or other biological liquids. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_DE69133382TT3</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>DE69133382TT3</sourcerecordid><originalsourceid>FETCH-epo_espacenet_DE69133382TT33</originalsourceid><addsrcrecordid>eNrjZNB0LM5MzMlPz6lMzi8oyi9JzcxLVUhJLVbwSC1ILMksySxWcNYNyywqLeZhYE1LzClO5YXS3AxKbq4hzh66qQX58anFBYnJqXmpJfEurmaWhsbGxhZGISHGxkQpAgBpZimJ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Asialoglycoproteine des Hepatitis C-Virus</title><source>esp@cenet</source><creator>GERVASE, BARBARA A ; THUDIUM, KENT B ; RALSTON, ROBERT O ; HALL, JOHN A ; MARCUS, FRANK</creator><creatorcontrib>GERVASE, BARBARA A ; THUDIUM, KENT B ; RALSTON, ROBERT O ; HALL, JOHN A ; MARCUS, FRANK</creatorcontrib><description>The following are claimed: (A) an isolated hepatitis C virus (HCV) a sialoglycoprotein (AG) selected from E1 and E2; (B) a method for purifying HCV AGs, which comprises (a) contacting a compsn. contg. HCV AGs with a mannose-binding protein, e.g. concanavalin A (ConA) or Galanthus nivalus agglutinin (GNA) and (b) isolating the portion of the compsn. which binds to the mannose-binding protein, e.g. by elution with mannose; (c) an assay kit for detecting the presence of HCV AGs, comprising (a) a solid support, (b) a mannose-binding protein, and (c) an antibody specific for the HCV AG, where one of the antibody and the mannose-binding protein is bound to the solid support; (D) a method for determining exposure to or infection by HCV, in which any HCV in a sample of body fluid is concd. by contact with a mannose-binding protein prior to assay; (E) a cell transformed with a vector for recombinant expression of a HCV AG, where the vector comprises a structural gene encoding a glycosoylation signal, a HCV AG, a regulatory sequence operable in the host cell and capable of regulating expressio fo the HCV AG, and a selectable marker, where the cell does not sialylate glycoproteins; and (F) a method for reducing or eliminatng the presence of HCV in plasma, serum or other biological liquids.</description><language>ger</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; HUMAN NECESSITIES ; HYGIENE ; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES ; MEASURING ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; ORGANIC CHEMISTRY ; PEPTIDES ; PHYSICS ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPIRITS ; TESTING ; VINEGAR ; WINE</subject><creationdate>2009</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20091008&DB=EPODOC&CC=DE&NR=69133382T3$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20091008&DB=EPODOC&CC=DE&NR=69133382T3$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>GERVASE, BARBARA A</creatorcontrib><creatorcontrib>THUDIUM, KENT B</creatorcontrib><creatorcontrib>RALSTON, ROBERT O</creatorcontrib><creatorcontrib>HALL, JOHN A</creatorcontrib><creatorcontrib>MARCUS, FRANK</creatorcontrib><title>Asialoglycoproteine des Hepatitis C-Virus</title><description>The following are claimed: (A) an isolated hepatitis C virus (HCV) a sialoglycoprotein (AG) selected from E1 and E2; (B) a method for purifying HCV AGs, which comprises (a) contacting a compsn. contg. HCV AGs with a mannose-binding protein, e.g. concanavalin A (ConA) or Galanthus nivalus agglutinin (GNA) and (b) isolating the portion of the compsn. which binds to the mannose-binding protein, e.g. by elution with mannose; (c) an assay kit for detecting the presence of HCV AGs, comprising (a) a solid support, (b) a mannose-binding protein, and (c) an antibody specific for the HCV AG, where one of the antibody and the mannose-binding protein is bound to the solid support; (D) a method for determining exposure to or infection by HCV, in which any HCV in a sample of body fluid is concd. by contact with a mannose-binding protein prior to assay; (E) a cell transformed with a vector for recombinant expression of a HCV AG, where the vector comprises a structural gene encoding a glycosoylation signal, a HCV AG, a regulatory sequence operable in the host cell and capable of regulating expressio fo the HCV AG, and a selectable marker, where the cell does not sialylate glycoproteins; and (F) a method for reducing or eliminatng the presence of HCV in plasma, serum or other biological liquids.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES</subject><subject>MEASURING</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PHYSICS</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPIRITS</subject><subject>TESTING</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2009</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZNB0LM5MzMlPz6lMzi8oyi9JzcxLVUhJLVbwSC1ILMksySxWcNYNyywqLeZhYE1LzClO5YXS3AxKbq4hzh66qQX58anFBYnJqXmpJfEurmaWhsbGxhZGISHGxkQpAgBpZimJ</recordid><startdate>20091008</startdate><enddate>20091008</enddate><creator>GERVASE, BARBARA A</creator><creator>THUDIUM, KENT B</creator><creator>RALSTON, ROBERT O</creator><creator>HALL, JOHN A</creator><creator>MARCUS, FRANK</creator><scope>EVB</scope></search><sort><creationdate>20091008</creationdate><title>Asialoglycoproteine des Hepatitis C-Virus</title><author>GERVASE, BARBARA A ; THUDIUM, KENT B ; RALSTON, ROBERT O ; HALL, JOHN A ; MARCUS, FRANK</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_DE69133382TT33</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>ger</language><creationdate>2009</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES</topic><topic>MEASURING</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PHYSICS</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPIRITS</topic><topic>TESTING</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>GERVASE, BARBARA A</creatorcontrib><creatorcontrib>THUDIUM, KENT B</creatorcontrib><creatorcontrib>RALSTON, ROBERT O</creatorcontrib><creatorcontrib>HALL, JOHN A</creatorcontrib><creatorcontrib>MARCUS, FRANK</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>GERVASE, BARBARA A</au><au>THUDIUM, KENT B</au><au>RALSTON, ROBERT O</au><au>HALL, JOHN A</au><au>MARCUS, FRANK</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Asialoglycoproteine des Hepatitis C-Virus</title><date>2009-10-08</date><risdate>2009</risdate><abstract>The following are claimed: (A) an isolated hepatitis C virus (HCV) a sialoglycoprotein (AG) selected from E1 and E2; (B) a method for purifying HCV AGs, which comprises (a) contacting a compsn. contg. HCV AGs with a mannose-binding protein, e.g. concanavalin A (ConA) or Galanthus nivalus agglutinin (GNA) and (b) isolating the portion of the compsn. which binds to the mannose-binding protein, e.g. by elution with mannose; (c) an assay kit for detecting the presence of HCV AGs, comprising (a) a solid support, (b) a mannose-binding protein, and (c) an antibody specific for the HCV AG, where one of the antibody and the mannose-binding protein is bound to the solid support; (D) a method for determining exposure to or infection by HCV, in which any HCV in a sample of body fluid is concd. by contact with a mannose-binding protein prior to assay; (E) a cell transformed with a vector for recombinant expression of a HCV AG, where the vector comprises a structural gene encoding a glycosoylation signal, a HCV AG, a regulatory sequence operable in the host cell and capable of regulating expressio fo the HCV AG, and a selectable marker, where the cell does not sialylate glycoproteins; and (F) a method for reducing or eliminatng the presence of HCV in plasma, serum or other biological liquids.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | ger |
| recordid | cdi_epo_espacenet_DE69133382TT3 |
| source | esp@cenet |
| subjects | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS TESTING VINEGAR WINE |
| title | Asialoglycoproteine des Hepatitis C-Virus |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T12%3A02%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=GERVASE,%20BARBARA%20A&rft.date=2009-10-08&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EDE69133382TT3%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |